Purity can differ between runs due to synthesis, purification, and analytical factors; here’s how to interpret and manage it.
Peptide purity is influenced by the efficiency of each solid-phase synthesis step. Variations in coupling yield, resin loading, and deprotection completeness can leave trace amounts of truncated or side-chain modified sequences that show up as minor peaks in analytical data.
The purification stage adds another source of variability. Column performance, gradient reproducibility, and the choice of stationary phase affect how well closely related impurities are separated. Small changes in mobile-phase composition or flow rate between runs can shift the apparent purity reported by HPLC.
Analytical measurement itself introduces differences. Calibration of UV detectors, integration settings, and the sensitivity of mass-spectrometry confirmation can lead to slightly different purity percentages even when the sample composition is unchanged. Always compare the same method and instrument settings when evaluating batch data.
For reliable bench work, treat the certificate of analysis as a starting point, not a final guarantee. Run a quick analytical check on receipt, document any deviations, and adjust downstream assays accordingly. Consistent handling, storage, and documentation help you account for the natural run-to-run variation inherent in peptide production.
Photo: USDAgov (BY) via flickr
For research use only. All products supplied by PepXtide are intended strictly for in-vitro laboratory research. They are not intended for human or veterinary use, consumption, or therapeutic application, and are not sold as drugs, food, or dietary supplements. These statements have not been evaluated by the FDA. Customers are responsible for compliance with applicable regulations in their jurisdiction.